Cardiometabolic Effects of Nigella sativa in Postmenopausal Women with Hypertension: A Prospective, Observational, Pilot Study.
- 2025-03-11
- Nutrients 17(6)
- Barbara Pala
- Giulia Nardoianni
- Paola Gualtieri
- Giulia Frank
- Marco Alfonso Perrone
- Laura Di Renzo
- Giuliano Tocci
- PubMed: 40338252
- DOI: 10.3390/nu17060985
Study Design
- Type
- Observational
- Sample size
- n = 52
- Population
- 52 postmenopausal women
- Methods
- Observational pilot study with two active groups (400 mg/day and 800 mg/day) and a control group, evaluated at baseline, 4 and 8 weeks
- Duration
- 8 weeks
- Funding
- Unclear
- Rigorous Journal
Background: Hypertension is a prevalent condition, impacting a significant amount of general population and contributing prominently to global mortality. Increasing attention has been directed towards phytotherapy products as potential complementary or alternative therapies for hypertension prevention and treatment. Among these, Nigella sativa (NS) has shown encouraging effects in improving cardiovascular parameters. This study aimed to evaluate the efficacy of NS supplementation in reducing seated office systolic blood pressure (BP) in postmenopausal women. We also explored the dose-dependent effects of this intervention on BP levels and metabolic parameters. Materials and Methods: We conducted an observational pilot study including 52 women, who were stratified into two active groups (n = 32) receiving two different dosages of NS (n = 16, age 54.2 ± 2.3 at 400 mg/day and n = 16, age 52.3 ± 2.4 at 800 mg/day) and a control group (n = 20, age 53.9 ± 3.0). Participants were evaluated at baseline (T0), at 4 (T1) and 8 weeks (T2) for office brachial and central BP, heart rate (HR), lipid profile, body weight, and menopausal symptoms. Results: NS supplementation significantly reduced office systolic and diastolic BP in a dose-dependent manner (p < 0.01), with more pronounced reductions at 800 mg/day. Improvements in climacteric symptoms and reduced HR were observed as early as T1, while metabolic parameters, including lipid profile and weight, showed significant changes at T2. Notably, the 800 mg/day dosage group also experienced significant reductions in weight and body mass index. Younger age, more recent menopausal transition, and elevated baseline HR were identified as predictors of a better response to treatment. Conclusions: NS supplementation demonstrates significant dose-dependent benefits in reducing office BP and improving metabolic parameters. These findings support the role of NS as an effective complementary therapy in hypertension management in postmenopausal women.
Research Insights
metabolic parameters, including lipid profile and weight, showed significant changes at T2
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 400 mg/day or 800 mg/day
improvements in climacteric symptoms and reduced HR were observed as early as T1
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 400 mg/day or 800 mg/day
the 800 mg/day dosage group also experienced significant reductions in weight and body mass index
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 400 mg/day or 800 mg/day
the 800 mg/day dosage group also experienced significant reductions in weight and body mass index
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 400 mg/day or 800 mg/day
NS supplementation significantly reduced office systolic and diastolic BP in a dose-dependent manner (p < 0.01)
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 400 mg/day or 800 mg/day
improvements in climacteric symptoms and reduced HR were observed as early as T1
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 400 mg/day or 800 mg/day
NS supplementation significantly reduced office systolic and diastolic BP in a dose-dependent manner (p < 0.01)
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 400 mg/day or 800 mg/day